Literature DB >> 16203150

Synthesis of functionalized 2-aryl-5-nitro-1H-indoles and their activity as bacterial NorA efflux pump inhibitors.

Siritron Samosorn1, John B Bremner, Anthony Ball, Kim Lewis.   

Abstract

In order to develop structure-activity relationships and to provide access to antibacterial agents for dual action studies, a variety of aryl group-substituted 2-aryl-5-nitro-1H-indoles were synthesized and the activity of the compounds assessed as inhibitors of the NorA multidrug resistance pump in the bacterium Staphylococcus aureus. The NorA protein from the major facilitator superfamily of efflux pumps confers resistance to a variety of structurally dissimilar antimicrobials such as norfloxacin, ethidium bromide, berberine and acriflavin. The compound [4-benzyloxy-2-(5-nitro-1H-2-yl)-phenyl]-methanol was the most potent pump inhibitor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16203150     DOI: 10.1016/j.bmc.2005.09.019

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  18 in total

1.  Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.

Authors:  Céline Vidaillac; Jean Guillon; Corinne Arpin; Isabelle Forfar-Bares; Boubakar B Ba; Jean Grellet; Stéphane Moreau; Daniel-Henri Caignard; Christian Jarry; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

Review 2.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

3.  Synthesis of Berberine-Efflux Pump Inhibitor Hybrid Antibacterials.

Authors:  John B Bremner; Michael J Kelso
Journal:  Synth Commun       Date:  2010-01-01       Impact factor: 2.007

4.  Controlling bacterial behavior with indole-containing natural products and derivatives.

Authors:  Roberta J Melander; Marine J Minvielle; Christian Melander
Journal:  Tetrahedron       Date:  2014-09-16       Impact factor: 2.457

5.  Advances in the structural studies of antibiotic potentiators against Escherichia coli.

Authors:  Gifty A Blankson; Ajit K Parhi; Malvika Kaul; Daniel S Pilch; Edmond J LaVoie
Journal:  Bioorg Med Chem       Date:  2019-06-04       Impact factor: 3.641

6.  Berberine-INF55 (5-nitro-2-phenylindole) hybrid antimicrobials: effects of varying the relative orientation of the berberine and INF55 components.

Authors:  Danuta Tomkiewicz; Gabriele Casadei; Jonah Larkins-Ford; Terence I Moy; James Garner; John B Bremner; Frederick M Ausubel; Kim Lewis; Michael J Kelso
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

7.  DFT and GA studies on the QSAR of 2-aryl-5-nitro-1H-indole derivatives as NorA efflux pump inhibitors.

Authors:  Yujie Dai; Xu Zhang; Xiuli Zhang; Huanjie Wang; Zhansheng Lu
Journal:  J Mol Model       Date:  2008-06-25       Impact factor: 1.810

8.  Structure-activity relationships of 2-aryl-1H-indole inhibitors of the NorA efflux pump in Staphylococcus aureus.

Authors:  Joseph I Ambrus; Michael J Kelso; John B Bremner; Anthony R Ball; Gabriele Casadei; Kim Lewis
Journal:  Bioorg Med Chem Lett       Date:  2008-07-02       Impact factor: 2.823

9.  Antibacterial activity of berberine-NorA pump inhibitor hybrids with a methylene ether linking group.

Authors:  Siritron Samosorn; Bongkot Tanwirat; Nussara Muhamad; Gabriele Casadei; Danuta Tomkiewicz; Kim Lewis; Apichart Suksamrarn; Therdsak Prammananan; Karina C Gornall; Jennifer L Beck; John B Bremner
Journal:  Bioorg Med Chem       Date:  2009-04-19       Impact factor: 3.641

10.  Antimicrobial and efflux pump inhibitory activity of caffeoylquinic acids from Artemisia absinthium against gram-positive pathogenic bacteria.

Authors:  Yiannis C Fiamegos; Panagiotis L Kastritis; Vassiliki Exarchou; Haley Han; Alexandre M J J Bonvin; Jacques Vervoort; Kim Lewis; Michael R Hamblin; George P Tegos
Journal:  PLoS One       Date:  2011-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.